Soft Tissue Sarcoma Market Research Report - Global Forecast till 2023

Report / Search Code: MRFR/HC3862-HCRR          Publish Date: October, 2018

Request Sample

| Price     | 1-user PDF : $ 4450.0 | Enterprise PDF : $ 6250.0 |

Description:

Soft Tissue Sarcoma Market Research Report – By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy), By Disease Type (Local, Regional, Metastatic Sarcoma), By Distribution Channel, By End User–Global Forecast till 2023

Market Scenario

Soft tissue sarcoma is a type of cancer that develops from tissues such as nerves, muscles, fats, blood vessels and deep skin tissues. Generally occurring in the muscles, tissues, and blood vessels that protect, support and surround the organs. Moreover, it is not categorized as tumor, but can be life-threatening if the cancer spreads to other parts of the body. There are around 50 different types of soft tissue sarcoma, such as adult fibrosarcoma, angiosarcoma, clear cell sarcoma, alveolar soft-part sarcoma, kaposi sarcoma, malignant mesenchymoma, rhabdomyosarcoma, and others.

Currently, there are very few products approved for the treatment of soft tissue sarcoma. For instance, in October 2016, U.S. Food and Drug Administration issued an accelerated approval notice for Eli Lilly and Company’s drug Lartruvo (Olaratumab) with Doxorubicin to treat certain types soft tissue carcinoma. Some of the drugs used for the treatment of soft tissue sarcoma include trabectedin (yondelis), sunitinib (sutent), sirolimus (rapamune), and doxorubicin (adriamycin), bevacizumab (avastin), and others.

Increase in the incidence and prevalence of different types of cancers, rising cases of soft tissue sarcoma, increasing R&D activities on drugs and other therapies, patent expiry of branded drugs, are some of the factors fuelling the growth of the soft tissue sarcoma market over the forecast period. However, stringent regulatory guidelines, adverse side effects of the treatment, and high cost for the radiotherapy and chemotherapy may hinder the growth of soft tissue sarcoma treatment market over the forecast period.

The methods for diagnosis of soft tissue sarcoma include some physical examination such as X-ray imaging, CT scan, MRI, ultrasound, PET scan and a biopsy. Such examinations in conjunction with other tests are important to plan a suitable treatment method for this condition.

The Global Soft Tissue Sarcoma Market is expected to grow at a CAGR of approximately 8.2% during the forecast period 2017-2023.

Intended Audience

- Soft Tissue Sarcoma Drug Suppliers
- Soft Tissue Sarcoma Drug Manufacturers
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities

Segmentation

The soft tissue sarcoma is segmented on the basis of treatment, disease type, distribution channel, and end-users.
On the basis of the treatment type, the soft tissue sarcoma treatment market is segmented into targeted therapy, chemotherapy, anti-angiogenesis drugs, radiation therapy. Furthermore, the radiation therapy is subcategorized into internal radiation therapy and external radiation therapy.

On the basis of the disease type, soft tissue sarcoma treatment market is segmented into local sarcoma, regional sarcoma, and metastatic sarcoma.

On the basis of the distribution channel, soft tissue sarcoma treatment market is segmented into hospital pharmacies, retail pharmacies and others.

On the basis of the end user, the global soft tissue sarcoma treatment market has been segmented into hospitals, oncology centers, and long term care centers.

**Key Players**

Some of key the players in the global soft tissue sarcoma market are GlaxoSmithKline plc (U.K), Eli Lilly and Company (U.S.), Pfizer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), and Celgene Corporation (U.S.) and others.

Various key players are active in the soft tissue sarcoma treatment market in terms of product launches, research, and development activities. For instance, in 2012, Threshold Pharmaceuticals Inc. signed a global license agreement for Evofosfamide, which is the most advanced first-line drug for soft tissue sarcoma with Merck KGaA. GSK’s Votrient (pazopanib) is approved for second-line treatment, and another drug Aldoxorubicin is approved as first-line drug for the treatment of soft tissue sarcoma. Currently, doxorubicin is commonly used for the treatment of soft tissue sarcoma.

**Research Methodology**

**Regional Analysis**

The global soft tissue sarcoma market consists of countries namely America, Europe, Asia Pacific, and the Middle East & Africa.

The Americas is projected to hold the largest share of the global soft tissue sarcoma market. Moreover, North America dominated the overall market in terms of revenue in 2016. According to American Cancer Society, approximately 12,390 people in 2016 were believed to suffer from soft tissue sarcoma and related cancer. High incidence rate of soft tissue sarcomas, increase in awareness about this condition, rise in focus on healthcare, and well-established healthcare infrastructure are some of the factors driving the market in North America.

Europe holds a key share in soft tissue sarcoma treatment market attributed to change in lifestyle,
increase in R&D activities for the development of new drugs. The European soft tissue sarcoma market is expected to have a tremendous growth during the forecast period.

The market in Asia Pacific is estimated to expand at a high CAGR during the forecast period, led by an increase in government spending on healthcare services in India and China. The Middle East & Africa is projected to expand during the forecast period, owing to the rise in investments by market players and increase in prevalence of soft tissue sarcomas.

Contents:

TABLE OF CONTENT

Chapter 1. Report Prologue
Chapter 2. Market Introduction
  2.1 Definition
  2.2 Scope of the Study
  2.2.1 Research Objective
  2.2.2 Assumptions
  2.2.3 Limitations
Chapter 3. Research Methodology
  3.1 Introduction
  3.2 Primary Research
  3.3 Secondary research
  3.4 Market Size Estimation
Chapter 4. Market Dynamics
  4.1 Drivers
  4.2 Restraints
  4.3 Opportunities
  4.4 Challenges
  4.5 Macroeconomic Indicators
  4.6 Treatment Trends & Assessment
Chapter 5. Market Factor Analysis
  5.1 Porter’s Five Forces Analysis
    5.1.1 Bargaining Power of Suppliers
    5.1.2 Bargaining Power of Buyers
    5.1.3 Threat of New Entrants
    5.1.4 Threat of Substitutes
    5.1.5 Intensity of Rivalry
    5.2 Value Chain Analysis
    5.3 Investment Feasibility Analysis
    5.4 Pricing Analysis
Chapter 6. Global Soft Tissue Sarcoma Market, by Treatment
  6.1 Introduction
  6.2 Targeted therapy
    6.2.1 Market Estimates & Forecast, 2016 – 2023
  6.3 Chemotherapy
    6.3.1 Market Estimates & Forecast, 2016 – 2023
6.4 Anti-angiogenesis Drug
6.4.1 Market Estimates & Forecast, 2016 – 2023

6.5 Radiation therapy
6.5.1 Market Estimates & Forecast, 2016 – 2023
6.5.2 Internal radiation therapy
6.5.2.1 Market Estimates & Forecast, 2016 – 2023
6.5.3 External radiation therapy
6.5.3.1 Market Estimates & Forecast, 2016 – 2023

Chapter 7. Global Soft Tissue Sarcoma Market, by Disease type
7.1 Introduction
7.2 Local sarcoma
7.2.1 Market Estimates & Forecast, 2017 – 2023
7.3 Regional sarcoma
7.3.1 Market Estimates & Forecast, 2017 – 2023
7.4 Metastatic sarcoma
7.4.1 Market Estimates & Forecast, 2017 – 2023

Chapter 8. Global Soft tissue sarcoma Market, by Distribution channel
8.1 Introduction
8.2 Hospital pharmacies
8.2.1 Market Estimates & Forecast, 2017 – 2023
8.3 Retail pharmacy
8.3.1 Market Estimates & Forecast, 2017 – 2023
8.4 Others

Chapter 9. Global Soft Tissue Sarcoma Market, by End User
9.1 Introduction
9.2 Hospitals
9.2.1 Market Estimates & Forecast, 2017 – 2023
9.3 Oncology centers
9.3.1 Market Estimates & Forecast, 2017 – 2023
9.4 Long Term Care Center
9.4.1 Market Estimates & Forecast, 2017 – 2023

Chapter. 10 Global Soft Tissue Sarcoma Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.1 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
LIST OF FIGURES

Figure 1 Research Process
Figure 2 Segmentation for Soft tissue sarcoma Market
Figure 3 Segmentation Market Dynamics for Soft tissue sarcoma Market
Figure 4 Global Soft tissue sarcoma Market Share, by Treatment 2016
Figure 5 Global Soft tissue sarcoma Market Share, by Disease types 2016
Figure 6 Global Soft tissue sarcoma Market Share, by Distribution Channel, 2016
Figure 7 Global Soft tissue sarcoma Market Share, by End Users, 2016
Figure 9 Global Soft tissue sarcoma Market Share, by Region, 2016
Figure 10 North America Soft tissue sarcoma Market Share, by Country, 2016
Figure 11 Europe Soft tissue sarcoma Market Share, by Country, 2016
Figure 12 Asia Pacific Soft tissue sarcoma Market Share, by Country, 2016
Figure 13 The Middle East & Africa Soft tissue sarcoma Market Share, by Country, 2016
Figure 14 Global Soft tissue sarcoma Market: Company Share Analysis, 2016 (%)
Figure 15 GlaxoSmithKline plc: Key Financials
Figure 16 GlaxoSmithKline plc: Segmental Revenue
Figure 17 GlaxoSmithKline plc: Geographical Revenue
Figure 18 F. Hoffmann-La Roche Ltd: Key Financials
Figure 19 F. Hoffmann-La Roche Ltd: Segmental Revenue
Figure 20 F. Hoffmann-La Roche Ltd: Geographical Revenue
Figure 21 Pfizer Inc.: Key Financials
Figure 22 Pfizer Inc.: Segmental Revenue
Figure 23 Pfizer Inc.: Geographical Revenue
Figure 24 Eli Lilly and Company: Key Financials
Figure 25 Eli Lilly and Company: Segmental Revenue
Figure 26 Eli Lilly and Company: Geographical Revenue
Figure 27 Johnson & Johnson Services, Inc.: Key Financials
Figure 28 Johnson & Johnson Services, Inc.: Segmental Revenue
Figure 29 Johnson & Johnson Services, Inc.: Geographical Revenue
Figure 30 Teva Pharmaceutical Industries Ltd: Key Financials
Figure 31 Teva Pharmaceutical Industries Ltd: Segmental Revenue
Figure 32 Teva Pharmaceutical Industries Ltd: Geographical Revenue
Figure 33 Bristol-Myers Squibb Company: Key Financials
Figure 34 Bristol-Myers Squibb Company: Segmental Revenue
Figure 35 Bristol-Myers Squibb Company: Geographical Revenue
Figure 36 Celgene Corporation: Key Financials
Figure 37 Celgene Corporation: Segmental Revenue
Figure 38 Celgene Corporation: Geographical Revenue